
模擬肺部規律伸縮環境,訓練幹細胞產生具修復潛力外泌體,登國際頂尖期刊《Biomaterials》
中國醫藥大學附設醫院開發「仿生呼吸動態拉伸培養平台」,透過模擬肺部規律伸縮環境訓練幹細胞,產生具修復潛力的外泌體以對抗肺纖維化(菜瓜布肺)。研究成果已刊登於國際期刊《Biomaterials》。
AI-generated summary
肺纖維化俗稱「菜瓜布肺」,會讓肺部組織逐漸變硬、失去彈性,現有藥物主要在於延緩疾病惡化。
中國醫藥大學附設醫院開發「仿生呼吸動態拉伸培養平台」,透過模擬肺部規律伸縮的環境,訓練幹細胞產生更具修復潛力的外泌體,可減少肺部纖維化及發炎反應,研究成果已刊登於國際生醫材料頂尖期刊《Biomaterials》。
肺纖維化俗稱「菜瓜布肺」,是一種會讓肺部組織逐漸變硬、失去彈性的疾病,患者常出現持續乾咳、呼吸困難等症狀,嚴重時甚至需要肺臟移植,其中,特發性肺纖維化較常發生於中高齡族群,吸菸、有家族病史者風險較高。
中國附醫院長周德陽指出,目前臨床已有抗纖維化藥物、氧氣治療及肺部復健等治療方式,但現有藥物主要在於延緩疾病惡化,仍難以讓已形成的纖維化組織恢復正常。因此,如何減少肺部纖維化、促進受損組織修復,是醫學界持續努力的重要方向。
周德陽帶領外科系副院長方信元、胸腔外科醫師陳建勳及異種移植轉譯研發中心副主任謝明佑團隊,成功開發「仿生呼吸動態拉伸培養平台」,運用特殊3D生物支架,搭配模擬呼吸節律的規律拉伸技術,讓幹細胞在接近肺部的動態環境中生長,如同讓細胞接受「呼吸訓練」。
研究結果發現,經過特殊培養的幹細胞,所分泌的外泌體含有更多具抗纖維化作用的miR-30,其含量約為傳統靜態培養的3.3倍,展現提升外泌體修復功能的潛力,這些外泌體進入受損肺組織後,能抑制造成纖維化的細胞過度活化,減少膠原蛋白堆積,另一方面則可調節免疫細胞,將促進發炎的反應轉向有利於組織修復的狀態,同時改善受損細胞的粒線體功能。
周德陽強調,此項研究將模擬人體器官自然運動的概念導入幹細胞培養,透過改變細胞生長環境,強化外泌體的抗纖維化作用,為再生醫學與肺纖維化治療提供新的研究方向,目前成果仍屬動物實驗階段,未來團隊將持續進行安全性與療效驗證,推動臨床轉譯,期望為肺纖維化患者帶來新的治療選擇。
AI outlook — possibilities, not facts
團隊將持續進行安全性與療效驗證,推動臨床轉譯
Likely · Within months

iFlytek Medical released AI patient management platform 3.0, using the Spark Medical large model to provide out-of-hospital rehabilitation management for discharged patients. Through the collaborative model of AI early warning, manual verification and doctor decision-making, the pain points of post-discharge care, review and risk monitoring of patients are solved. It has been implemented in more than 300 hospitals across the country.

On October 29, Aikang Group released the "2026 Pink Report on Chinese Women's Health" in Chongqing. The report shows that the detection rate of female breast nodules reached 47.06%, an increase of more than 2.5 times compared with 2019, and shows a trend of getting younger. Experts recommend that women over the age of 35 undergo regular screening to reduce the risk of disease through early prevention and early screening.

Taiwan is facing the challenges of a super-aging population and an increase in the dementia population. The Ministry of Health and Welfare announced that it will promote the "Dementia Prevention and Care Policy Framework and Action Plan 3.0" starting from 2026, with the goal of reaching 888 dementia-friendly levels by 2035, and improving resource gaps among counties and cities through cross-department cooperation and accurate diagnosis and treatment.
Well-known health care product brand Swisse has been recalled in Australia due to excessive lead content in two batches of "anti-sugar pills". The brand responded that the products involved did not enter China through general trade, but experts pointed out that there are regulatory blind spots in cross-border e-commerce and purchasing agents channels, and brand trust has been damaged.

Since this year, the Ministry of Finance has specially allocated funds to support free influenza vaccination for elderly people aged 65 and above and primary and secondary school students in compulsory education in rural areas. Experts explain vaccination policies, objects, locations and service optimization measures.

Propofol, an anesthetic drug commonly known as the "milk shot", has recently been exposed as being used by clinics to treat insomnia, raising concerns about addiction and safety. Minister of Health and Welfare Shi Chongliang emphasized that propofol cannot be used to treat insomnia, and the Ministry of Health and Welfare does not rule out a comprehensive census to maintain patient safety.